



ASSOCIAZIONE ITALIANA
CONTRO LEUCEMIE
LINFOMI E MIELOMA

LEUKEMIA 2022

Rome, Hotel NH Collection - Vittorio Veneto

May 5-6, 2022

AIL President: G. Toro

Coordinators: A.M. Carella, S. Amadori



AUSPICES:



fondazione GIMEMA onlus
per la promozione e lo sviluppo della ricerca scientifica
sulle malattie ematologiche. **FRANCO MANDELLI**



SIE - Società Italiana di Ematologia

LEUKEMIA2022

Rome, Hotel NH Collection - Vittorio Veneto

May 5-6, 2022

AIL President: G. Toro
Coordinators: A.M. Carella, S. Amadori

Welcome message

We welcome you to the 11th annual Conference on "Leukemia 2022". We are very pleased to inform you that the Conference will be held in cooperation with the Italian Association against Leukemia, Lymphomas and Myeloma (AIL), the largest Italian voluntary organization dedicated to funding blood cancer research and patient services. The aim of the Conference is to bring together highly qualified Italian and international scientists and clinicians to discuss emerging paradigms and breakthroughs at the forefront of biology and treatment across the spectrum of blood cancers, including acute and chronic leukemias, myelodysplastic syndromes, myeloproliferative disorders, lymphomas and myelomas. Attendees will hear of recent findings in basic and clinical research, from the molecular basis of blood cancers to novel therapies emerging in the clinic, through ample interaction with key experts in the field.

SERGIO AMADORI



ANGELO MICHELE CARELLA



SCIENTIFIC BOARD

Sergio Amadori
Angelo M. Carella
Fabio Ciceri
Antonio Cuneo
Fabrizio Pane
Alessandro Rambaldi
Valeria Santini
Alessandro M. Vannucchi

AIL SCIENTIFIC COMMITTEE

William Arcese
Fabrizio Pane
Pier Giuseppe Pelicci
Francesco Rodeghiero
Giorgina Specchia

Faculty

Sergio
Renato
Matteo
Francesca
Massimo
Francesco
Angelo Michele
Michele
Sabina
Fabio
Paolo
Marta
Elena
Antonio
Antonio
Valerio
Ilaria
Matteo G.
Brunangelo
Felicetto
Andrés J.M.
Robin
Matilde Y.
Paolo
Paola
Carmelo
Alessandro
Franco
Francesco
Giovanni
Francesca R.
Cristina
Pellegrino
Fabrizio
Francesco
Giovanni
Alessandro
Alessandro
Luigi
Davide
Gianantonio
Giovanni
Valeria
Simona
Sergio
Simona
Mario
Giuseppe
Alessandro M.
Adriano
Umberto
Maria Teresa
Pier Luigi

AMADORI
BASSAN
BERSANELLI
BONIFAZI
BRECCIA
BUCCISANO
CARELLA
CAVO
CHIARETTI
CICERI
CORRADINI
COSCIA
CRISÀ
CUNEO
CURTI
DE STEFANO
DEL GIUDICE
DELLA PORTA
FALINI
FERRARA
FERRERI
FOÀ
FOLLO
GHIA
GUGLIEMELLI
GURNARI
ISIDORI
LOCATELLI
MANNELLI
MARTINELLI
MAURO
MECUCCI
MUSTO
PANE
PASSAMONTI
PIZZOLO
PULSONI
RAMBALDI
RIGACCI
ROSSI
ROSTI
ROTI
SANTINI
SICA
SIRAGUSA
SOVERINI
TIRIBELLI
TORO
VANNUCCHI
VENDITTI
VITOLO
VOSO
ZINZANI

Rome, Italy
Mestre (VE), Italy
Rozzano (MI), Italy
Bologna, Italy
Rome, Italy
Rome, Italy
Genoa, Italy
Bologna, Italy
Rome, Italy
Milan, Italy
Milan, Italy
Turin, Italy
Novara, Italy
Ferrara, Italy
Bologna, Italy
Rome, Italy
Rome, Italy
Rozzano (MI), Italy
Perugia, Italy
Naples, Italy
Milano, Italy
Rome, Italy
Bologna, Italy
Milan, Italy
Florence, Italy
Cleveland, USA
Pesaro
Rome, Italy
Florence, Italy
Meldola (FC), Italy
Rome, Italy
Perugia, Italy
Bari, Italy
Naples, Italy
Varese, Italy
Verona, Italy
Rome, Italy
Bergamo, Italy
Rome, Italy
Bellinzona, Svizzera
Bologna, Italy
Parma, Italy
Florence, Italy
Rome, Italy
Palermo, Italy
Bologna, Italy
Udine, Italy
Palermo, Italy
Florence, Italy
Rome, Italy
Turin, Italy
Rome, Italy
Bologna, Italy



Thursday, May 5, 2022

11.00 am **Greetings from AIL President** G. Toro

11.15 am **LECTURE**
From biology to therapy: progress in acute promyelocytic leukemia
Introduced by S. Amadori, A. M. Carella M.T. Voso

SESSION I ACUTE MYELOID LEUKEMIA

Chairmen: **S. Amadori, S. Sica**

11.30 am Emerging targeted therapies and combinations A. Venditti
11.45 am Novel strategies to treat older patients F. Buccisano
12.00 pm Is it maintenance therapy necessary? A. Isidori
12.15 pm Novel approaches for p53-mutant AML G. Martinelli
12.30 pm Immune-based therapies: new horizons A. Curti

12.45 pm *Discussion*

01.00 pm **Break**

SESSION II CHRONIC LYMPHOCYTIC LEUKEMIA

Chairmen: **A. Cuneo, G. Pizzolo**

01.45 pm Update on molecular pathogenesis D. Rossi
02.00 pm Emerging prognostic/predictive factors I. Del Giudice
02.15 pm Autoimmune complications M. Coscia
02.30 pm Lessons from clinical trials P. Ghia
02.45 pm Salvage therapy F.R. Mauro

03.00 pm *Discussion*

SESSION III MYELOPROLIFERATIVE NEOPLASMS

Chairmen: **V. De Stefano, A.M. Vannucchi**

03.15 pm Post-MPN acute leukemia: a persistently unmet need P. Guglielmelli
V. De Stefano

03.30 pm Re-assessing the treatment paradigm of PV
03.45 pm Thrombosis and bleeding: rationale and therapeutic perspectives S. Siragusa
F. Passamonti

04.00 pm Beyond JAK inhibitors in MF F. Mannelli

04.15 pm Hypereosinophilias with and without genetic rearrangement

04.30 pm *Discussion*

04.45 pm **Break**

JOHN GOLDMAN LECTURE

NPM1 - Mutated AML: from bench to bedside
Introduced by A.M. Carella B. Falini

SESSION IV CHRONIC MYELOID LEUKEMIA

Chairmen: **A.M. Carella, F. Pane**

05.30 pm Moving beyond the Sokal and ELTS scores: baseline molecular factors in CML prognostic S. Soverini

05.45 pm Imatinib versus a 2nd generation TKI for the first line of therapy: how we can tip the balance between efficacy and quality of life M. Tiribelli
G. Rosti

06.00 pm The new guidelines for the management of CML M. Breccia
06.15 pm Future perspectives of novel therapies

06.30 pm *Discussion*

Friday, May 6, 2022

SESSION V ACUTE LYMPHOBLASTIC LEUKEMIA

Chairmen: **R. Foà, A. Rambaldi**

08.30 am	New insights in T/Myeloid mixed-phenotype acute Leukemia (T/M MPAL)	C. Mecucci
08.45 am	Can we predict the chemosensitivity of ALL?	G. Roti
09.00 am	MRD driven strategy in Adult ALL	R. Bassan
09.15 am	New treatment strategies for Ph-like ALL	S. Chiaretti
09.30 am	New treatment strategies in Ph-Negative ALL?	F. Ferrara
09.45 am	Novel Allo-transplant options in adult ALL	F. Bonifazi
10.00 am	Current status and future perspectives on the role of CAR-T cells in childhood ALL	F. Locatelli
10.20 am	<i>Discussion</i>	

SESSION VI MYELOYDYSPLASTIC SYNDROMES

Chairmen: **P. Musto, V. Santini**

10.50 am	Recent advances in somatic mutations and altered signaling in MDS cell	M.Y. Follo
11.05 am	Towards a new prognostication of MDS	M. Bersanelli
11.20 am	Artificial Intelligence to improve clinical decision making in hematological malignancies	M.G. Della Porta
11.35 am	Is it possible to stop therapy in MDS (high risk vs low risk)?	E. Crisà
11.50 am	Vexas syndrome and myelodysplastic syndromes	C. Gurnari
12.05 pm	<i>Discussion</i>	

SESSION VII EXPANDING HORIZONS FOR IMMUNOTHERAPY IN ONCO-HEMATOLOGY

Chairmen: **F. Ciceri, L. Rigacci**

12.20 pm	State of the art	A.J.M. Ferreri
12.35 pm	CAR-T in Large B cell NHL	P. Corradini
12.50 pm	CAR-T in Indolent NHL	A. Pulsoni
01.05 pm	New recombinant antibodies in Lymphomas	P.L. Zinzani
01.20 pm	New Drugs in NHLs	U. Vitolo
01.35 pm	Next generation immunotherapy in Multiple Myeloma	M. Cavo
01.50 pm	<i>Discussion</i>	
02.10 pm	Closing Remarks	

with unrestricted educational grant of:



GENERAL INFORMATION

MEETING VENUE

NH Hotel Vittorio Veneto

Corso d'Italia, 1 - 00198 Rome, Italy

Phone +39 06 84951

OFFICIAL LANGUAGE

The official language of the congress will be the Italian.

REGISTRATION

The registration is free. It is possible to register on the website www.ercongressi.it, section Congressi/2022.

BADGE AND CERTIFICATE OF ATTENDANCE

All registered participants and speakers will be given a badge which must be worn to be admitted to the scientific sessions.

A certificate will be given to all participants at the end of the meeting.

ITALIAN CME CREDITS

An Italian CME application has been submitted as follows:

- Provider Studio ER Congressi SRL: ID 828-282400.
- No. **9,1 CME** credits for Physicians (disciplines: Hematology, Oncology, Clinical pathology, Internal Medicine) and Biologists.
- Educational objective: "linee guida-protocolli-procedure".

CHANGES

Parts of the program may be changed without notice.

ORGANIZING SECRETARIAT

Studio E.R. Congressi

Via De' Poeti, 1/7 - 40124 Bologna, Italy

Ph +39 051 4210559 - Fax +39 051 4210174

E-mail: ercongressi@ercongressi.it

www.ercongressi.it